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Interferon regulatory factor (IRF) 3 is a transcription
factor that binds the interferon-sensitive response ele-
ment (ISRE) and is activated by Toll-like receptor 3
(TLR3) and TLR4. We have found that a dominant neg-
ative form of IB kinase 2 and a mutant form of IB,
which acts as a super-repressor of NF-B, blocked acti-
vation of the ISRE by the TLR4 ligand lipopolysaccha-
ride but not the TLR3 ligand poly(I-C). TLR4 failed to
activate the ISRE in mouse embryonic fibroblasts bear-
ing a targeted deletion of p65, whereas the response to
TLR3 in these cells was normal. The p65 subunit of
NF-B was detected in the lipopolysaccharide-activated
but not poly(I-C)-activated ISRE-binding complex. Fi-
nally, p65 promoted transactivation of gene expression
by IRF-3. These results therefore indicate that IRF-3-
mediated activation of the ISRE by TLR4 but not TLR3
requires the p65 subunit of NF-B.
The discovery of human Toll-like receptors (TLRs)1 has in-
creased our understanding of the molecular basis to innate
immunity. TLRs allow the host to differentiate between groups
of pathogens and to tailor its initial response accordingly. At
least 10 different TLRs occur in humans (1). Most of their
ligands have been assigned, the majority of which are so-called
pathogen-associated molecular patterns. Two of the best stud-
ied TLRs are TLR4, which recognizes lipopolysaccharide (LPS)
from Gram-negative bacteria, and TLR3, which recognizes the
viral double-stranded RNA mimic poly(I-C) (2–5). TLRs are
defined by external leucine-rich repeats and a cytoplasmic Toll/
interleukin-1 receptor (TIR) domain (1). Upon stimulation the
TLRs recruit TIR domain-containing adaptor molecules via
homotypic interactions with receptor TIR domains. This ini-
tiates signal transduction culminating in the activation of tran-
scription factors and an increase in immune and inflammatory
gene expression. A key question concerns specificity in signal
transduction by different TLRs, because although common
gene sets are induced by TLRs, specific patterns of gene ex-
pression have been demonstrated for TLR2, TLR3, and TLR4,
which may provide a molecular basis for the tailoring of innate
immune response (6–8).
Myeloid differentiation factor 88 (MyD88) was the first TIR
domain-containing adaptor to be described. It is a general
adaptor for TLRs, and loss of MyD88 prevents signal transduc-
tion through most of the TLRs. The only known exceptions are
TLR3 and TLR4, which both initiate a so-called “MyD88-inde-
pendent” pathway (5, 9). This alternative pathway is mediated
by another adaptor termed TIR domain-containing adaptor-
inducing IFN (TRIF) or TIR-containing adaptor molecule 1
(10–13). It is involved in the activation of the transcription
factor interferon regulatory factor 3 (IRF-3), which binds the
interferon-sensitive response element (ISRE) and induces a
subset of genes, including IFN (2, 14, 15). Although TRIF is
recruited to both TLR4 and TLR3, the recently described TRIF-
related adaptor molecule (16), also called TIR-containing adap-
tor molecule 2 (17), which activates IRF-3 as well as NF-B, is
specific for TLR4 signaling and presumably acts upstream of
TRIF. TLR4 also recruits MyD88 and an additional adaptor
named MyD88 adapter-like (Mal) or TIR domain-containing
adapter protein, which is also required for TLR2 signaling
(18–21). Both Mal and MyD88 would appear to be involved in
the rapid activation of NF-B by TLR4, whereas TRIF, in
addition to regulating IRF-3, mediates later activation (12, 13,
20, 21).
In its inactive form IRF-3 is constitutively present in a latent
cytoplasmic pool. Upon stimulation with poly(I-C), IRF-3 be-
comes phosphorylated in its C terminus, which presumably
reveals the previously hidden dimerization domain (22). LPS
does not induce C-terminal phosphorylation but appears to
causes N-terminal phosphorylation (23, 24). The nature of this
phosphorylation and the responsible kinase is still uncertain.
In the case of the C-terminal phosphorylation two IB kinase
(IKK)-related proteins, IKK and TANK-binding kinase 1, have
recently been identified as possible components of the virus-
and TLR3-activated kinase complex for IRF-3 (25, 26).
In this study we have found a key role for the NF-B subunit
p65 in the IRF-3-mediated induction of the ISRE by TLR4 but
not TLR3. p65 promoted transactivation of gene expression by
IRF-3. TLR4 and TLR3 therefore differ in their mechanism of
ISRE induction.
EXPERIMENTAL PROCEDURES
Cell Culture, Plasmids, and Reagents—HEK293 and U373 cell lines
were purchased from the Centre for Applied Microbiology & Research
(Salisbury, UK), the HEK293-TLR3 cell line was kind gift of Katherine
Fitzgerald (University of Massachusetts Medical School). The mouse
embryonic fibroblasts (MEFs) with a targeted deletion in p65 and wild
type MEFs were a kind gift from Ron Hay (University of St. Andrews,
Fife, Scotland), and MEFs with a deletion of the  subunit of the
interferon-/ receptor on a 129SV/Ev genetic background and their
parental MEFs were a gift from Otto Haller (University of Freiburg,
Freiburg, Germany). The cells were grown in Dulbecco’s modified Ea-
* This work was supported by the Science Foundation Ireland. The
costs of publication of this article were defrayed in part by the payment
of page charges. This article must therefore be hereby marked “adver-
tisement” in accordance with 18 U.S.C. Section 1734 solely to indicate
this fact.
‡ To whom correspondence should be addressed. Tel.: 353-1-608-
2449; Fax: 353-1-677-2400; E-mail: wietekc@tcd.ie.
1 The abbreviations used are: TLR, Toll-like receptor; LPS, lipopo-
lysaccharide; TIR, Toll/interleukin-1 receptor; IFN, interferon ; IRF,
interferon regulatory factor; ISRE, interferon-sensitive response ele-
ment; IKK, IB kinase; MEF, mouse embryonic fibroblast; hTLR, hu-
man TLR; CBP, cAMP-responsive element-binding protein-binding
protein.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 278, No. 51, Issue of December 19, pp. 50923–50931, 2003
© 2003 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 50923
 at IR
eL (Trinity College Dublin), on September 30, 2009
w
w
w
.jbc.org
D
ow
nloaded from
 
FIG. 1. Synergism between MyD88 or Mal and IRF-3 in the activation of the ISRE. A, the inhibitory effects of plasmids encoding
dominant negative versions of IRF-3 (NIRF-3, 50 ng) were tested in HEK293 cells that were co-transfected with 100 ng of the ISRE- or B
luciferase constructs and CD4-TLR4 (50 ng) (left panel) and in HEK-TLR3 cells, which were stimulated for 6 h with poly(I-C) (25 g/ml) to induce
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gle’s medium supplemented with 10% fetal calf serum, 2 mM L-gluta-
mine, and 100 units ml1 gentamycin and maintained at 37 °C in a
humidified atmosphere of 5% CO2, 200 mg ml
1 of the neomycin analog
G418 was added to maintain HEK293-TLR3 cells. The cells were seeded
at 0.5  105 to 105 ml1 for experiments and treated as indicated in
figure legends. LPS from Escherichia coli serotype O26:B6 and poly(I-C)
were purchased from Sigma.
The NF-B luciferase construct bearing five repeats of the B con-
sensus was a gift from Dr. R. Hofmeister (Universitaet Regensburg,
Regensburg, Germany). The ISRE luciferase construct, which has five
repeats of the ISRE sequence from the ISG15 promoter, was purchased
from Clontech (Palo Alto, CA). Constructs for the IRF-3 transactivation
assay, p-55UASGLuc, Gal4-DBD, and Gal4-IRF-3 were a kind gift of
Takashi Fujita (Tokyo Metropolitan Institute of Medical Science, To-
kyo, Japan). The chimeric CD4-TLR4 and CD4-TLR3 expressing vec-
tors were a gift from Ruslan Medzhitov (Yale University School of
Medicine). Mal was expressed from pDC304, and MyD88 was from
pCDNA3.1. The plasmid encoding TRIF was a kind gift from Shizuo
Akira (Osaka University, Osaka, Japan). The construct comprising
hemagglutinin-tagged p65 and the IB-SR expression vector were kind
gifts from Keith Ray (GlaxoSmithKline, Stevenage, UK). Constructs
encoding the dominant negative version IKK2, IKK2KA, and human
TLR3 (hTLR3) were obtained from Tularik (San Francisco, CA). Ex-
pression constructs bearing IRF-3 and NIRF-3 were kind gifts of John
Hiscott (McGill University, Montreal, Canada).
Transfection-based Reporter Gene Assays—HEK293, U373, and
MEFs were seeded at 1–2 104 cells well1 in 96-well plates, incubated
overnight, and transfected using GeneJuice transfection reagent (No-
vagen, Madison, WI) according to the manufacturer’s instructions with
a total amount of 300 ng of DNA well1 comprising 100 ng of reporter
gene construct, plasmid DNA of interest, and empty vector as filler
DNA. For transactivation assays 80 ng of p-55UASGLuc were applied in
combination with 100 ng of either Gal4-DBD or Gal4-IRF-3 and addi-
tional plasmids as indicated in figure legends. The cells were lysed in
passive lysis buffer (Promega, Southampton, UK) for 15 min. At 24 or
48 h post-transfection, the extracts were monitored for firefly luciferase
activity following standard protocols. 40 ng well1 Renilla reniformis
luciferase construct was used as internal control for transfection effi-
ciency. The activities were expressed as fold activation over unstimu-
lated empty vector controls (ctrl). The experiments were carried out in
triplicate with error bars indicating standard deviations.
Electrophoretic Mobility Shift Assays—U373 cells were grown in
15-cm dishes and treated as indicated in figure legends, and their
nuclear extracts were prepared as previously described with minor
modifications (27). Specifically, the samples were homogenized using a
Dounce homogenizer (80 strokes at 4 °C). Following the addition of the
high salt buffer, the samples were rotated for 30 min at 4 °C. 10 g of
nuclear protein was incubated for 30 min with 10,000 cpm of double-
stranded [-32P]ATP ISRE oligonucleotide (5-GAT CGG GAA AGG
GAA ACC GAA ACT GAA-3) in hybridization buffer (10 mM Tris-HCl,
pH 7.5, 100 mM NaCl, 1 mM EDTA, 5 mM dithiothreitol, 4% glycerol, and
100g ml1 nuclease free bovine serum albumin) containing 2 g ml1
of poly(dI-dC) as nonspecific competitor. Supershifting antibodies spe-
cific for p65 (SC-8008X) and IRF-3 (SC-9082X) were added to the
nuclear extracts 1 h prior to hybridization with the oligonucleotide. The
samples were kept on ice at all stages. Protein-DNA complexes were
run on a 5% native polyacrylamide gel, and complex formation was
detected with autoradiography.
RESULTS
The TLR4 Adaptors MyD88 and Mal Enhance ISRE-depend-
ent Gene Expression—We were interested in comparing IRF-3
activation by TLR4 and TLR3. To examine this process we used
three systems comprising transfection of HEK293 cells with a
CD4-TLR4 fusion protein, which is constitutively active,
HEK293 cells rendered sensitive to poly(I-C) by stable trans-
fection with TLR3, and addition of the ligands LPS and
poly(I-C) to U373 cells, which express TLR3 and TLR4 consti-
tutively. Fig. 1A demonstrates that transfection with a plasmid
encoding a dominant negative version of IRF-3 blocked CD4-
TLR4 and TLR3/poly(I-C)-stimulated induction of a reporter
gene, luciferase, linked to five ISRE sites from the ISG15
promoter (left-hand panel) but did not inhibit the expression of
luciferase linked to five NF-B-binding sites (right-hand
panel). These results indicate that the ISRE luciferase re-
sponse involves IRF-3.
We next probed the link between the adaptors MyD88, Mal,
and TRIF with IRF-3. Fig. 1B demonstrates how overexpres-
sion of each of the proteins on their own affected ISRE- or
B-linked reporter gene expression. In agreement with other
studies (10, 11) expression of TRIF led to the strongest activa-
tion of the ISRE, causing a 200-fold induction over controls. By
comparison, MyD88 and Mal had only marginal effects on the
ISRE but were much better inducers of NF-B when compared
with TRIF. Overexpression of IRF-3 only induced the ISRE
response. However, as shown in Fig. 1C, when concentrations
of Mal or MyD88 unable to activate the ISRE were co-expressed
with IRF-3, a clear synergy was observed in ISRE induction
(Fig. 1C, left-hand panel). Mal enhanced the IRF-3 alone re-
sponse by 5-fold, whereas MyD88 had a 7-fold effect. IRF-3 had
no effect on NF-B either alone or in combination with Mal or
MyD88, as expected (Fig. 1C, right-hand panel).
NF-B Is Required for IRF-3 Activation by LPS but Not
poly(I-C)—The synergism observed between MyD88 or Mal and
IRF-3 with respect to ISRE activation suggested that TLR4
signaling to IRF-3 might involve NF-B, because Mal and
MyD88 are both NF-B activators. To examine this we tested
specific inhibitors of the NF-B pathway for their effects on
TLR4-mediated and, for comparison, TLR3-mediated signal
transduction to the ISRE. We used IB-SR, a mutant form of
IB (S32A/S36A), which cannot undergo phosphorylation and
acts as a super-repressor of NF-B, and a kinase inactive
mutant of IKK 2 (IKK2KA), which acts as a dominant negative
inhibitor. Interestingly, both agents inhibited CD4-TLR4-stim-
ulated ISRE and, as expected, NF-B-mediated gene induction
(Fig. 2A). Strikingly, neither had an effect on ISRE activation
by poly(I-C) in TLR3-transfected HEK293 cells but, as ex-
pected, blocked NF-B activation, although the inhibitory ef-
fect of IKK2KA reached a maximum of only 50% (Fig. 2B).
Similar results were obtained when ISRE- and B-dependent
expression was measured in U373 cells. LPS-mediated activa-
tion of the ISRE was repressed by both IKK2KA and IB-SR,
whereas the effect of poly(I-C) was not impaired by either of
these agents (Fig. 2C, left-hand panel). NF-B activation by
LPS and poly(I-C) in U373 was blocked by both IKK2KA and
IB-SR (right-hand panel) with IKK2KA again having a lesser
effect than the IB-SR on the poly(I-C) response.
TLR4 Fails to Induce ISRE-dependent Gene Expression in
the Absence of p65—We further tested the significance of
NF-B in the TLR4 response using p65-deficient cells. Fig. 3
(left-hand panel) demonstrates how CD4-TLR4 activates
NF-B in wild type MEFs, whereas the effect in p65-deficient
MEFs was impaired, as expected. TLR3 signaling to NF-B
expression from ISRE and B luciferase constructs (right panel). B, HEK293 cells were co-transfected with the ISRE (gray histobars) or the B
luciferase constructs (white histobars) and increasing amounts (25, 50, and 100 ng) of plasmids encoding MyD88, Mal, TRIF, and IRF-3. C,
expression of the ISRE and the B luciferase constructs in HEK293 cells was assayed when plasmids encoding MyD88 (25 ng) or Mal (25 ng) were
expressed with (white histobars) or without (black histobars) co-transfected IRF-3 (25 ng). In all cases 0.5 106 cells were transiently transfected
with a total of 300 ng of DNA in 96-well microtiter plates. In all experiments, the cells were transfected for up to 48 h. Unstimulated cells
transfected with an empty vector was used as control (ctrl). The measured luciferase reporter gene activity values were normalized for transfection
efficiency with R. reniformis luciferase. The data shown are the means  standard deviations from triplicate determinations. All of the results
shown are representative of three separate experiments.
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activated by poly(I-C) in MEFs transfected with TLR3 was
decreased in p65-deficient cells. Importantly, a different result
was obtained using the ISRE luciferase construct, as shown in
Fig. 3 (right-hand panel). The ISRE response to TLR4 was
almost abolished in the p65-deficient MEFs relative to wild
type controls. We were unable to test LPS itself on MEFs
because in wild type cells the activation of the ISRE was
marginal (data not shown). The effect of poly(I-C), however,
was similar in wild type and in p65-deficient cells. This result
provides additional evidence that NF-B, and in particular the
p65 subunit, is required for signaling by TLR4 but not TLR3 to
the ISRE.
p65 Interacts with IRF-3 at the ISRE and Promotes Trans-
activation—We next tested whether p65 was part of the IRF-
3-containing ISRE activation complex. We used the ISRE from
the ISG15 promoter (as used in the ISRE luciferase construct)
in an electrophoretic mobility shift assay on nuclear extracts
from LPS- or poly(I-C)-stimulated U373 cells. As shown in Fig.
4A, we observed complex formation at the ISRE oligonucleotide
following stimulation with either LPS (lane 4) or poly(I-C) (lane
7). Incubation of the extract with an IRF-3-specific antibody
abolished DNA binding, confirming the presence of IRF-3 in
each complex (lanes 5 and 8). Importantly, a p65-specific anti-
body prevented ISRE complex formation in extracts from LPS-
FIG. 2. Effects of IKK2KA and the IB-SR on ISRE activation by TLR4 and TLR3. A, 0.5 106 HEK293 cells were co-transfected with
plasmids encoding CD4-TLR4 (100 ng), ISRE or B luciferase constructs, and increasing amounts (10 and 25 ng) of plasmids encoding dominant
negatives IKK2KA and IB-SR. B, 0.5 106 HEK293-TLR3 cells transfected with either the ISRE or the B luciferase construct and increasing
amounts (10 and 25 ng) of the dominant negative IKK2KA and IB-SR were stimulated with poly(I-C) (25g/ml) for 6 h. C, 105 U373 cells were
co-transfected with either the ISRE or the B luciferase construct and the dominant negative IKK2KA (60 ng) or IB-SR (60 ng). The cells were
stimulated with LPS (500 ng/ml) or poly(I-C) (25 g/ml) for 6 h. After up to 48 h of transfection, the cell lysates in all experiments were measured
for luciferase reporter gene activity, and the retrieved data were normalized to R. reniformis luciferase values. Unstimulated cells transfected with
an empty vector was used as control (ctrl). The data shown are the means  standard deviations from triplicate determinations and are
representative of two to three experiments.
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treated cells (lane 6) but had only a marginal effect on extracts
from poly(I-C)-treated cells (lane 9). The supershifting ability of
the p65-specific antibody was confirmed with a B site-contain-
ing oligonucleotide and LPS-stimulated U373 and THP-1 nu-
clear cell extracts (data not shown).
We also addressed what role p65 might have on the function-
ing of IRF-3. For this we used an IRF-3 transactivation assay.
This assay involved transfecting cells with a plasmid encoding
a fusion protein comprising the transactivation domain of
IRF-3 fused to the DNA-binding domain of Gal4. When acti-
vated, this fusion protein drives a Gal4-controlled luciferase
reporter gene co-transfected into the cells. Fig. 4B demon-
strates that increasing expression of p65 in HEK293 cells dose-
dependently promoted IRF-3-mediated transactivation. This
effect was blocked by the IB-SR but not the dominant negative
IKK2KA (Fig. 4C). Overexpressed IB-SR presumably seques-
ters p65 in the cell, thereby preventing it from enhancing IRF-3
transactivation activity. Taken together these data indicate
that p65 and IRF-3 interact in a complex at the ISRE as a
consequence of TLR4 but not TLR3 signaling and that p65
promotes transactivation by IRF-3.
Finally, we wanted to exclude the possibility that activation
of the ISRE in our experiments is predominantly driven via a
type I interferon feedback loop through activation of ISGF3. We
therefore transfected MEFs bearing a targeted disruption of
the  subunit of the interferon-/ receptor (IFNAR1/ MEFs)
and their corresponding wild type MEFs with the B and ISRE
luciferase constructs and tested TLR3 and TLR4 responses.
TLR4 and TLR3 signaling to either ISRE or NF-B was com-
parable in both IFNAR1/-deficient and wild type cells (Fig.
4D), indicating that the ISRE construct serves primarily as an
IRF-3 read-out. Consistent with our data in HEK293 and U373
cells, upon co-transfection with the IB-SR only the TLR4-
stimulated ISRE response was decreased, whereas TLR3 signal-
ing remained unaltered (Fig. 4E). It should be noted that the
parental MEFs of the IFNAR1/ MEFs, although clearly evi-
dent, were less responsive compared with the wild type MEFs,
which were the corresponding controls for the p65-deficient cells.
DISCUSSION
The results from this study indicate a difference between
TLR4- and TLR3-mediated activation of the ISRE. TLR4 has
an absolute requirement for NF-B in this process, with p65
occurring in the ISRE binding complex with IRF-3, whereas the
TLR3-induced ISRE response is NF-B-independent. We first
suspected NF-B involvement in the pathway to IRF-3 from
TLR4 when we observed that Mal or MyD88 synergize with
overexpressed IRF-3 in ISRE activation. Both of these adaptors
target NF-B. NF-B involvement was confirmed by the inhib-
itory effect of IKK2KA and IB-SR on the TLR4 response and
most compellingly in cells from p65-deficient mice, which were
unresponsive in terms of TLR4 signaling to the ISRE but were
normal for TLR3.
The necessity for cooperation between NF-B and IRF-3 has
been outlined in other studies (14, 28, 29). Interestingly, p65 is
redundant for induction of the IFN promoter after poly(I-C)
data stimulation but is absolutely essential for LPS-stimulated
IFN expression (30). These observations at a minimum indi-
cate that NF-B and IRF-3 must cooperate in TLR4 signaling
but not TLR3 signaling to a gene whose promoter contains an
ISRE but also support our evidence for a function for p65 in
TLR4- but not in TLR3-mediated ISRE activation. Addition-
ally, in an earlier study it has been shown that the necessity for
p65 at the IFN promoter could be overcome with a chimera
comprising the N-terminal DNA-binding domain of IRF-3 and
the N-terminal p65 transactivation domain (14). This again
argues for a direct cooperation between IRF-3 and p65 at the
ISRE, with the role of p65 to promote transactivation. In sup-
port of this model we found that the inhibition of the NF-B
pathway in IFNAR1/ MEFs cells blocks TLR4 signaling to
the ISRE. Additionally, we detected both p65 and IRF-3 in the
LPS/TLR4-induced activation complex at the ISRE.
FIG. 3. The p65 subunit of NF-B is required for TLR4-induced activation of the ISRE. 0.5 106 wild type MEFs (wt) or MEFs with a
targeted deletion of p65 (p65/) were seeded in 96-well microtiter plates and transfected with the ISRE or B luciferase constructs (100 ng) with
either CD4-TLR4 (50 ng) or hTLR3 for 24 h. The cells transfected with hTLR3 (0.5 ng) were subsequently stimulated with 1g/ml poly(I-C) for 7 h.
Unstimulated cells transfected with an empty vector were used as control (ctrl). Luciferase activity was determined in cell lysates and normalized
for transfection efficiency with R. reniformis luciferase activity. The data shown are the means  standard deviations from triplicate determina-
tions. An identical result was observed in a subsequent experiment.
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FIG. 4. Interaction between NF-B and IRF-3. A, nuclear extracts prepared from 105 U373 cells treated for 6 h with LPS (1 g/ml) or poly(I-C)
(25 g/ml) or left untreated were analyzed in a electrophoretic mobility shift assay using an oligonucleotide comprising the ISRE from the ISG15
promoter. The arrow indicates protein/DNA complexes. The extracts were preincubated with antibodies against IRF-3 or p65 as indicated. These
results are representative of three separate experiments. B, 106 HEK293 cells were co-transfected with a construct bearing the Gal4 upstream
activation sequence fused to the luciferase reporter gene (100 ng), an expression vector for Gal4-IRF-3 (80 ng), or the Gal4 DNA-binding domain
on its own Gal4-DBD (80 ng) and expression vector for p65 in increasing amounts (5, 25, and 50 ng). C, 106 HEK293 cells transfected with Gal4
luciferase construct (100 ng), the expression vector for Gal4-IRF-3 (80 ng), and p65 (50 ng) were additionally transfected with expression vectors
for the dominant negative form of IKK2 (IKK2KA 20 ng) and the IB-SR (20 ng). D, 0.5 106 wild type MEFs (wt) or MEFs with bearing a deletion
of IFNAR1 (IFNAR1/) were seeded in 96-well microtiter plates and transfected with 100 ng of the ISRE-or the B luciferase constructs and with
either CD4-TLR4 (60 ng) or hTLR3 (0.5 ng) for 24 h. The cells transfected with hTLR3 were stimulated with 1g/ml poly(I-C) for 7 h. E, IFNAR1/
MEFs were co-transfected with ISRE luciferase, CD4-TLR4, or hTLR3, respectively, and increasing doses of IB-SR (10 ng and 30 ng).
Unstimulated cells transfected with an empty vector were used as control (ctrl). In all experiments cell lysates were prepared 24 h after transfection
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An interaction between p65 and IRF-3 at the ISRE could be
mediated by the IRF-3 co-activators cAMP-responsive element-
binding protein-binding protein (CBP) or p300. IRF-3 relies on
recruitment of these co-activators not only to reduce export
from the nucleus but moreover for transcriptional activation
(15, 31). The histone acetylase function of CBP is vital for
binding to the ISRE (32). CBP has been shown to interact with
both IRF-3 and p65 (31, 33, 34) and to recruit the two tran-
scription factors to distinct sites on CBP (35, 36). Simultaneous
binding of p65 with IRF-3 could have a synergistic effect and
possibly alter the conformation or steric orientation of IRF-3 at
CBP to modify transcriptional activity of the complex. It is
possible that other subunits of NF-B, such as c-Rel or RelB,
can also bind to this complex and promote ISRE activity, and
we are currently investigating their involvement. However,
because of the availability of p65-deficient cells, we focused on
the role of p65 in this study.
The mechanism by which LPS activates IRF-3 via TLR4 is
FIG. 4—continued
and assayed for luciferase reporter gene activity, and the obtained values were normalized against the R. reniformis luciferase activity for
transfection efficiency. Luciferase activity in cells transfected with a Gal4-DBD expression vector was in all cases below the control values of cells
transfected with the Gal4-IRF-3 construct. The data shown are the means  standard deviations of triplicate determinations. The results shown
are representative of three independent experiments.
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still uncertain, although other studies have also indicated dif-
ferences between LPS and viral stimuli or poly(I-C) in this
process (23, 37, 38). LPS appears to cause N-terminal phospho-
rylation of IRF-3, whereas the activation induced by poly(I-C)
is more potent and results in phosphorylation of the C terminus
(23, 37). It is possible that IRF-3 phosphorylated in its C
terminus does not require p65 for it to enhance transcription,
whereas N-terminally phosphorylated IRF-3 does. Recently,
two independent studies have implicated two members of the
IKK family, IKK and TANK-binding kinase 1, as crucial me-
diators in virus- or poly(I-C)-induced IRF-3 activation and have
suggested that IKK is an activating kinase for IRF-3 and
IRF-7 (25, 26). This process seems to be separate from any
effect these kinases might have on IKK2, which is a substrate
for both IKK and TANK-binding kinase 1. IKK2 was shown
not to be capable of phosphorylating IRF-3 when immunopre-
cipitated from cells. Our evidence also rules out a role for IKK2
in the IRF-3 activation process triggered by poly(I-C). With
respect to LPS it has been shown that ISRE binding activity
induced by LPS in IKK-deficient MEFs was unaltered com-
pared with wild type MEFs, which argues against a role for
IKK in LPS-dependent IRF-3 activation, consistent with the
evidence that LPS does not cause C-terminal phosphorylation
(39). It has, however, been suggested that TRIF is involved in
IKK activation (26) and is required for IRF-3 activation by
LPS, as revealed by the failure of LPS to induce IRF-3 dimer-
ization in TRIF-deficient cells (12, 13). Further experiments
will be needed to resolve this issue, and it is likely that there is
additional complexity in adaptor usage in this process. Fur-
thermore because LPS can still activate the ISRE in the ab-
sence of Mal and MyD88 (20, 21), TRIF and/or TRIF-related
adaptor molecule (16), also known as TIR-containing adaptor
molecule 2 (17) or TIR domain-containing adapter protein (40),
may provide the signal to NF-B in the absence of MyD88 and
Mal required for ISRE activation by TLR4. The failure of TLR2
to activate IRF-3 (8) is presumably due to the fact that it
signals via MyD88 and Mal and does not utilize TRIF (20, 21).
IRF-3 activation upon LPS stimulation has also been dem-
onstrated in Gal4-IRF-3 transactivation studies and in nuclear
translocation assays (41, 42). How LPS triggers these events is
still not known. One possibility we are exploring is that p65
and IRF-3 interact directly, or via CBP as stated above, and is
required for these responses.
Although the signaling pathways induced by TLR4 and
TLR3 therefore differ, both lead to ISRE activation allowing for
IFN expression. Clearly, the ISRE can be activated by differ-
ent transcription factor complexes including IRF-7 and ISGF3,
a trimeric complex comprising STAT1, STAT2, and IRF-9 (22,
43, 44). Its promiscuity may allow for fine-tuning of responses
in different biological contexts. It is also possible that the
p65/IRF-3 dimer targets an additional set of genes, increasing
the repertoire of responses to LPS.
LPS induces IRF-3- and NF-B-dependent production of
IFN, which in an autocrine manner via the IFNAR1 receptor
and ISFG3 activates the ISRE (8, 38). Inhibition of NF-B
could block LPS-stimulated IFN production and hence inter-
fere with this positive feedback loop. However, our study points
to a more direct effect because cells deficient in the -chain of
the IFN/ receptor remain responsive to TLR4 and TLR3
signaling. Given our other data demonstrating that p65-de-
pleted cells are impaired in the ISRE response to TLR4 but not
TLR3 and that p65 could be detected in the LPS-activated
ISRE-binding complex and could promote transactivation by
IRF-3, we conclude that LPS directly induces a p65-IRF-3
complex for ISRE activation, whereas the poly(I-C) response is
direct only toward IRF-3.
In conclusion, our study provides the first demonstration
that p65 is absolutely required for activation of the ISRE by
TLR4 but not TLR3. The emerging differences in signaling by
TLR4 and TLR3 as well as other TLRs will continue to improve
our understanding of the fine-tuning of the innate
immune response.
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